Total Payments
$2,334
2024 Payments
$119.39
Companies
5
Transactions
21
Payment Breakdown by Category
Food & Beverage$2,034 (87.1%)
Consulting$300.00 (12.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,034 | 19 | 87.1% |
| Consulting Fee | $300.00 | 2 | 12.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,609 | 15 | $0 (2024) |
| Biogen, Inc. | $300.00 | 2 | $0 (2021) |
| Horizon Therapeutics plc | $183.77 | 2 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $124.99 | 1 | $0 (2019) |
| GENZYME CORPORATION | $116.17 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $119.39 | 1 | Novartis Pharmaceuticals Corporation ($119.39) |
| 2023 | $183.77 | 2 | Horizon Therapeutics plc ($183.77) |
| 2021 | $150.00 | 1 | Biogen, Inc. ($150.00) |
| 2019 | $775.19 | 7 | Novartis Pharmaceuticals Corporation ($500.20) |
| 2018 | $664.58 | 6 | Novartis Pharmaceuticals Corporation ($664.58) |
| 2017 | $440.78 | 4 | Novartis Pharmaceuticals Corporation ($324.61) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/07/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $119.39 | General |
| Category: Neurology | ||||||
| 04/17/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $119.40 | General |
| Category: UPLIZNA | ||||||
| 04/17/2023 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $64.37 | General |
| Category: UPLIZNA | ||||||
| 07/16/2021 | Biogen, Inc. | TYSABRI (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: NEUROLOGY | ||||||
| 10/21/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $96.24 | General |
| 09/27/2019 | Biogen, Inc. | TYSABRI (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: NEUROLOGY | ||||||
| 08/22/2019 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Immunology | ||||||
| 07/16/2019 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Food and Beverage | In-kind items and services | $113.79 | General |
| Category: NEUROSCIENCE | ||||||
| 07/11/2019 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Food and Beverage | In-kind items and services | $116.77 | General |
| Category: NEUROSCIENCE | ||||||
| 05/07/2019 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Food and Beverage | In-kind items and services | $76.37 | General |
| Category: NEUROSCIENCE | ||||||
| 01/24/2019 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Food and Beverage | In-kind items and services | $97.03 | General |
| Category: NEUROSCIENCE | ||||||
| 12/11/2018 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $113.95 | General |
| 10/30/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Food and Beverage | In-kind items and services | $99.89 | General |
| Category: NEUROSCIENCE | ||||||
| 08/09/2018 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $77.96 | General |
| 06/21/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Food and Beverage | In-kind items and services | $124.26 | General |
| Category: NEUROSCIENCE | ||||||
| 05/03/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Food and Beverage | In-kind items and services | $124.26 | General |
| Category: NEUROSCIENCE | ||||||
| 04/16/2018 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $124.26 | General |
| 04/24/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | GILENYA (Drug) | Food and Beverage | In-kind items and services | $105.11 | General |
| Category: NEUROSCIENCE | ||||||
| 04/12/2017 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Food and Beverage | In-kind items and services | $95.96 | General |
| Category: NEUROSCIENCE | ||||||
| 03/09/2017 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $123.54 | General |
| 02/08/2017 | GENZYME CORPORATION | LEMTRADA (Drug) | Food and Beverage | In-kind items and services | $116.17 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
About Dr. Edwin Tasch, MD
Dr. Edwin Tasch, MD is a Neurology healthcare provider based in Santa Clara, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407933369.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edwin Tasch, MD has received a total of $2,334 in payments from pharmaceutical and medical device companies, with $119.39 received in 2024. These payments were reported across 21 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($2,034).
Ad
Practice Information
- Specialty Neurology
- Location Santa Clara, CA
- Active Since 10/31/2006
- Last Updated 12/17/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1407933369
Products in Payments
- GILENYA (Drug) $646.51
- MAYZENT (Drug) $306.93
- TYSABRI (Biological) $300.00
- UPLIZNA (Drug) $183.77
- SOLIRIS (Drug) $124.99
- KESIMPTA (Drug) $119.39
- LEMTRADA (Drug) $116.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.